Healthcare Private Placement and M&A Transactions Review Week Ending August 31, 2025

Wugen: The company raised $115 million of venture funding in a deal led by Fidelity Management & Research Company on August 27, 2025. Tybourne Capital Management, RiverVest Venture Partners, Lightchain Capital, and Abingworth also participated in the round. The company is a developer of off-the-shelf cell therapy technology designed to treat hematologic and solid tumor cancers.

Plexium: The company raised $60 million of venture funding from undisclosed investors on August 25, 2025, putting the company’s pre-money valuation at an estimated $1.98 billion. The company is a developer of protein-degrading therapeutics designed to treat cancer and other serious diseases.

Assort Health: The company raised $50 million of Series B venture funding from undisclosed investors on August 26, 2025, putting the company’s pre-money valuation at $700 million. The company is a developer of a conversational artificial intelligence platform designed to augment and automate call center operations for patient care.

Mid-Atlantic BioTherapeutics: The company closed on $50 million of an undisclosed targeted amount of venture funding from Legend Innovation Life Science Fund on August 25, 2025. The company is a developer of a novel anti-infective therapeutic platform designed to eradicate infectious diseases through immunotherapy.

Cyted Health: The company raised $44 million of Series B venture funding in a deal led by EQT Life Sciences, Advent Life Sciences and British Business Bank on August 29, 2025. BGF (Financial Services) and Morningside Group also participated in the round. The company is a developer of a digital diagnostic infrastructure platform designed to detect the early stages of cancer.

Leal Therapeutics: The company closed on $30 million of an undisclosed targeted amount of venture funding in a deal led by SV Health Investors on August 27, 2025. Chugai Venture Fund, PhiFund Ventures, Newpath Partners, Alexandria Venture Investments and Euclidean Capital also participated in the round. The company is a developer of novel therapeutic services for major central nervous system indications.

Medical Brain: The company raised $20 million of venture funding in the form of convertible debt from undisclosed investors on August 28, 2025. The company is a developer of a clinical decision support platform designed to monitor and address patient health in real-time.

Arya Health: The company raised $18 million of venture funding from undisclosed investors on August 29, 2025. The company is a developer of a compensation platform intended to offer tools for managing healthcare workers.

Barti: The company raised $12 million of Series A venture funding in a deal led by Five Elms Capital on August 25, 2025. Recall Capital, Correlation Ventures and other undisclosed investors also participated in the round. The company is a developer of medical records system software designed for storing healthcare records electronically.

Xanadu Bio: The company raised $11 million of Series B venture funding from undisclosed investors on August 27, 2025. The company is an operator of a nanoparticle delivery platform intended to offer delivery of mRNA and other nucleic acids.

Orion Biotechnology: The company raised $6.8 million of venture funding from Opus8 and other undisclosed investorson August 26, 2025. The company is an operator of a clinical-stage biotechnology company, intended to develop novel medical treatments and therapies for the prevention and treatment of global health issues.

CascadeBio: The company raised $5.4 million of venture funding from undisclosed investors on August 25, 2025. The company is a developer of enzyme immobilization kits designed to improve the sustainability and efficiency of existing processes of chemical manufacturing.

Sampling Human: The company raised an estimated $4.49 million of venture funding in a deal led by Fundomo on August 25, 2025. B3 Holding, i&i Biotech Fund, Valhalla Ventures, and bpd partners also participated in the round. The company is a developer of a genetic analysis technology intended for complex single-cell data.

Rimidi: The company raised $3.25 million of venture funding in the form of convertible debt from Album VC and other undisclosed investors on August 27, 2025. The company is a digital health business that provides an EHR-integrated clinical management platform for chronic disease management and remote patient monitoring.

Frontier Bio: The company raised an undisclosed amount of venture funding from Made Noble Companies, Propel and Immortal Dragons on August 29, 2025. Break Off Capital, Boutique Venture Partners, Hatcher+, MicroVentures, Artesian Venture Partners, Mistletoe, Alchemist Accelerator, Tim Wagner, Nishant Bhat, Jonathan Yaffe, Tiffany To, Mark Hamalainen, Iman Jeddi, Miles Albert, 100 Plus Capital and other undisclosed investors also participated in the round. The company is a developer of lab-grown human tissues intended to replace animal studies.

Waltz Health / EVERSANA: The company was acquired by EVERSANA, via its financial sponsors ACE & Company, JLL Partners, Pantheon International, Water Street Healthcare Partners, Revelation Partners and North Sky Capital, through a $6 billion LBO on August 26, 2025. The company is an operator of a digital health platform that uses AI-driven marketplaces to help lower prescription drug costs and improve the patient experience.

OrganOx / Terumo: The company reached a definitive agreement to be acquired by Terumo for an estimated $1.5 billion on August 25, 2025. The company is a developer and manufacturer of organ preservation and transplantation devices designed to reduce liver decay.

ScPharmaceuticals / MannKind: The company reached a definitive agreement to be acquired by MannKind for $337.5 million on August 25, 2025. ScPharmaceuticals Inc is a pharmaceutical business focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs.

Melinta Therapeutics / Cormedix: The company reached a definitive agreement to be acquired by Cormedix for $300 million on August 7, 2025. The company is a manufacturer of novel small-molecule antibiotics focused on the treatment of resistant infections.

Quipt Home Medical / Forager Capital Management: The company entered into a definitive agreement to be acquired by Forager Capital Management through an estimated $215.9 million public-to-private LBO on August 25, 2025. Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients.

10763942 Canada / Pacific Software: The company was acquired by Pacific Software for an undisclosed amount on August 26, 2025. The company is a developer of small molecules and psychoactive compounds for the treatment of neurological and psychiatric disorders.

Arietta.ai / SePRO: The company was acquired by SePRO, via its financial sponsor Stanley Capital and Goldman Sachs Asset Management, through an LBO on August 26, 2025 for an undisclosed amount. The company is a developer of an AI-powered healthcare platform that speeds-up medical decision making and data analysis for the life science industry.

Aster Insights / Zephyr AI: The company was acquired by Zephyr AI for an undisclosed amount on August 26, 2025. The company is a developer of a health informatics-based tool designed to accelerate the discovery, development and delivery of personalized medicine for cancer therapies.

HealthConnected / Visma: The company was acquired by Visma, via its financial sponsors Stefan Alois Margolis, Altaroc Partners, Hg, Pantheon International, GIC Private, ICG Enterprise Trust, New York City Public Pension Funds, Intermediate Capital Group, Patria Private Equity Trust, Troll Ventures, Flexstone Partners, Government Pension Fund Norway, Warburg Pincus, Vind, CPP Investments, TPG, Alpha Leonis Partners and AustralianSuper, through an LBO on August 27, 2025 for an undisclosed amount. The company is a developer of an information and communication technology platform intended for primary care providers.

IGM Biosciences / Concentra Biosciences: The company was acquired by Concentra Biosciences for $82.9 Million on August 29, 2025. IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases.

MARCo Health / Eduscape: The company was acquired by Eduscape for an undisclosed amount on August 25, 2025. The company is a developer of an AI-powered social robot designed to provide accessible and affordable mental health support.

PatientPoint / Advent International: The company entered into a definitive agreement to be acquired by Advent International through an LBO on August 25, 2025 for over $1.4 billion. The company is a developer of a patient engagement platform intended to serve the healthcare sector.

PharmaDirections / Danforth Advisors: The company was acquired by Danforth Advisors, via its financial sponsors Avesi Partners and Harris Preston & Partners, through an LBO on August 25, 2025 for an undisclosed amount. The company is a provider of virtual drug development services intended to drive concepts from laboratory proof of concept to clinical proof of concept.

Swiss Cardio Technologies / Abacus Medicine: The company was acquired by Abacus Medicine, a subsidiary of Siemens, for an undisclosed amount on August 25, 2025. The company is a developer of a novel, standardized ultra-low-volume cardioplegic solution, Cardioplexol.